Prevalence and Influencing Factors of Depression in Patients with Parkinson’s Disease

,; Li, Ling; Wang, Zhengyang; ,; You, Zhifei; ,; Huang, Jing; ,

doi:10.5152/alphapsychiatry.2023.231253

Cited by 2 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PD is pathologically characterized by the loss of dopaminergic neuron in the substantia nigra (SN) and the presence of α-synuclein protein accumulation. PD has a prevalence in people aged 65 and above of about 1.7% (Li et al, 2023 ). One study has predicted that by 2030, the number of PD patients will reach 4.94 million in China, accounting for about 50% of the global incidence (Yue et al, 2024 ).…”

Section: Introductionmentioning

confidence: 99%

Early dopaminergic replacement treatment initiation benefits motor symptoms in patients with Parkinson's disease

Li,

Dong,

Dong

et al. 2024

Front. Hum. Neurosci.

View full text Add to dashboard Cite

BackgroundParkinson's disease (PD) generally progresses slowly, but it is controversial whether delaying treatment accelerates the progression.ObjectiveDetermine the correlation between the time of dopaminergic replacement treatment initiation and the severity of clinical symptoms in PD, including motor and non-motor symptoms.MethodsPD patients were divided between 155 people who were diagnosed de novo and 165 PD patients receiving dopamine replacement therapy. Basic patient characteristics included gender, age, age at onset, disease duration, and the time of dopaminergic replacement treatment initiation. We used MDS-UPDRS scores to evaluate the severity of motor symptoms and we also used the scale to assess the severity of non-motor symptoms such as cognition, mood, sleep, and quality of life.ResultsThe mean time between symptom onset and the initiation of drug treatment was 31.0 (22.5) months. After adjusting for age, sex, age at onset, and disease duration, we found that the MDS-Unified Parkinson's Disease Rating Scale (UPDRS)-III score increased faster in the de novo group with a similar disease duration (F = 8.7, p = 0.0034) than the treatment group. The cumulative incidence of progression to H-Y score 3 in de novo PD group over disease duration was 39.7% in 50months and 92.2% in 100 months, while in treated group such cumulative incidence was 15.5% in 50 months, 51.4% in 100 months and 81.5% in 150 months. The cumulative incidence of patients in the de novo PD group was higher than that in the treated group (p = 0.001), suggesting that untreated patients were more likely to progress to the advanced stages. Symptoms onset, the time between symptom onset and treatment initiation, age, sex, and disease duration explained 28.95% of the total variation in the MDS-UPDRS-III score for motor symptoms. In drug-naïve patients, the time between symptom onset and treatment initiation explained 20.1% of the total variation in the MDS-UPDRS-III score for motor symptoms (t = 6.15, p < 0.001).ConclusionsThese data in our study showed that early dopaminergic replacement treatment have played a positive role in PD patients, while dopaminergic replacement delayed treatment might be detrimental to motor symptoms and non-motor state of PD patient. Recognizing early stage symptoms of PD and early diagnosis are of great significance to treatment.

show abstract

Section: Introductionmentioning

confidence: 99%